Information Provided By: 
Fly News Breaks for September 29, 2016
ADHD
Sep 29, 2016 | 09:59 EDT
Cantor Fitzgerald analyst Mara Goldstein downgraded Alcobra Pharma to Hold from Buy based on the clinical hold placed on the program by the FDA. The "information void" is likely to keep the shares trading at a very low multiple of cash, Goldstein tells investors in a research note. The analyst thinks the stock can trade around $2, her new price target.
News For ADHD From the Last 2 Days
There are no results for your query ADHD
